Spero Therapeutics (NASDAQ:SPRO) Insider Esther Rajavelu Sells 18,442 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 18,442 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $2.20, for a total transaction of $40,572.40. Following the completion of the sale, the insider owned 1,100,008 shares of the company’s stock, valued at approximately $2,420,017.60. The trade was a 1.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Esther Rajavelu also recently made the following trade(s):

• On Friday, November 7th, Esther Rajavelu sold 40,270 shares of Spero Therapeutics stock. The stock was sold at an average price of $2.37, for a total value of $95,439.90.

Spero Therapeutics Trading Up 7.0%

Shares of Spero Therapeutics stock opened at $2.29 on Thursday. Spero Therapeutics, Inc. has a 12 month low of $0.51 and a 12 month high of $3.22. The firm has a market capitalization of $129.02 million, a P/E ratio of -2.90 and a beta of 1.45. The business’s fifty day simple moving average is $2.35 and its 200 day simple moving average is $2.24.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.12. The business had revenue of $5.44 million during the quarter, compared to the consensus estimate of $12.00 million. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. Analysts predict that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Trading of Spero Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. purchased a new stake in shares of Spero Therapeutics in the 2nd quarter worth approximately $43,000. Dimensional Fund Advisors LP bought a new stake in shares of Spero Therapeutics during the third quarter valued at approximately $55,000. Quadrature Capital Ltd bought a new position in Spero Therapeutics in the 2nd quarter valued at approximately $90,000. Axxcess Wealth Management LLC purchased a new stake in Spero Therapeutics during the 2nd quarter valued at $94,000. Finally, XTX Topco Ltd bought a new stake in shares of Spero Therapeutics in the 2nd quarter worth $100,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on SPRO. Zacks Research downgraded Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 11th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Spero Therapeutics presently has an average rating of “Reduce”.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.